Recursion Completes Merger with Exscientia, Expanding AI Drug Discovery Platform
Recursion merges with Exscientia, creating a vertically integrated AI platform for drug discovery innovation.
The merger of AI-driven drug discovery companies Recursion (Nasdaq: RXRX) and Exscientia has been finalized, making Exscientia a wholly owned subsidiary of Recursion. This integration establishes a vertically integrated platform for drug discovery. As part of the merger, Exscientia's ADSs (Nasdaq: EXAI) have ceased trading and are being delisted.
Recursion CEO Chris Gibson highlighted the expanded pipeline, which includes over 10 clinical/preclinical programs and significant partnerships with milestones exceeding $450M so far. Exscientia’s former CEO David Hallett emphasized the merger's ability to accelerate drug discovery through proprietary data and iterative modeling.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Medicus Pharma reicht Phase‑2b/3‑Protokoll für Teverelix bei der FDA ein
Fresenius Kabi erhält FDA-Warnschreiben nach Fehlern bei der Untersuchung aseptischer Verarbeitung in der Anlage Melrose Park
Discussion